Picture loading failed.

Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab, targets the Clever-1 receptor, known to be expressed on immunosuppressive macrophages in the tumour microenvironment and circulating in soluble form, and which is capable of directly inhibiting T-cell activation.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-066-1mg 1mg 3090
GMP-Bios-ab-066-10mg 10mg Inquiry
GMP-Bios-ab-066-100mg 100mg Inquiry
GMP-Bios-ab-066-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody
INN Name Bexmarilimab
TargetSTAB1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesFaron Pharmaceuticals
Conditions Approvedna
Conditions ActiveSolid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis
Conditions Discontinuedna
Development Techna